Fulcrum Capital LLC Acquires 4,255 Shares of Edwards Lifesciences Co. (NYSE:EW)

Fulcrum Capital LLC grew its stake in Edwards Lifesciences Co. (NYSE:EW - Free Report) by 3.5% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 126,267 shares of the medical research company's stock after purchasing an additional 4,255 shares during the quarter. Edwards Lifesciences comprises about 2.0% of Fulcrum Capital LLC's holdings, making the stock its 17th biggest holding. Fulcrum Capital LLC's holdings in Edwards Lifesciences were worth $9,152,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Farmers & Merchants Investments Inc. grew its position in shares of Edwards Lifesciences by 21.1% in the 4th quarter. Farmers & Merchants Investments Inc. now owns 134,341 shares of the medical research company's stock worth $9,945,000 after buying an additional 23,409 shares during the period. Lockheed Martin Investment Management Co. purchased a new stake in Edwards Lifesciences in the fourth quarter worth about $4,499,000. Alyeska Investment Group L.P. purchased a new stake in Edwards Lifesciences in the fourth quarter worth about $49,038,000. Equitable Trust Co. increased its stake in shares of Edwards Lifesciences by 10.9% during the fourth quarter. Equitable Trust Co. now owns 73,042 shares of the medical research company's stock valued at $5,407,000 after purchasing an additional 7,154 shares in the last quarter. Finally, Simplify Asset Management Inc. purchased a new position in shares of Edwards Lifesciences during the fourth quarter valued at approximately $5,979,000. 79.46% of the stock is owned by hedge funds and other institutional investors.

Edwards Lifesciences Stock Performance

Shares of NYSE EW traded down $0.32 during midday trading on Tuesday, hitting $77.78. 4,093,296 shares of the stock traded hands, compared to its average volume of 5,185,185. The firm has a market capitalization of $45.63 billion, a P/E ratio of 11.16, a PEG ratio of 4.82 and a beta of 1.12. Edwards Lifesciences Co. has a one year low of $58.93 and a one year high of $95.25. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. The firm has a 50-day moving average of $73.49 and a two-hundred day moving average of $72.57.

Edwards Lifesciences (NYSE:EW - Get Free Report) last posted its earnings results on Wednesday, April 23rd. The medical research company reported $0.64 earnings per share for the quarter, beating analysts' consensus estimates of $0.60 by $0.04. The company had revenue of $1.41 billion for the quarter, compared to the consensus estimate of $1.40 billion. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. Edwards Lifesciences's revenue was up 6.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.66 earnings per share. On average, equities analysts forecast that Edwards Lifesciences Co. will post 2.45 EPS for the current fiscal year.

Insider Buying and Selling

In other news, CFO Scott B. Ullem sold 11,250 shares of Edwards Lifesciences stock in a transaction dated Wednesday, March 26th. The stock was sold at an average price of $70.87, for a total transaction of $797,287.50. Following the transaction, the chief financial officer now directly owns 30,387 shares of the company's stock, valued at $2,153,526.69. The trade was a 27.02% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Daniel J. Lippis sold 400 shares of the business's stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $69.48, for a total value of $27,792.00. Following the transaction, the vice president now owns 22,588 shares of the company's stock, valued at approximately $1,569,414.24. This trade represents a 1.74% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 59,012 shares of company stock valued at $4,224,717. 1.29% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several analysts recently weighed in on EW shares. Royal Bank of Canada restated an "outperform" rating and issued a $85.00 price target on shares of Edwards Lifesciences in a research note on Wednesday, February 12th. Truist Financial cut their target price on Edwards Lifesciences from $78.00 to $75.00 and set a "hold" rating on the stock in a research note on Friday, April 11th. Piper Sandler raised their price target on Edwards Lifesciences from $80.00 to $83.00 and gave the company an "overweight" rating in a report on Tuesday, May 13th. Evercore ISI lowered their price target on Edwards Lifesciences from $75.00 to $73.00 and set an "in-line" rating for the company in a research report on Wednesday, February 12th. Finally, Wall Street Zen downgraded shares of Edwards Lifesciences from a "buy" rating to a "hold" rating in a research report on Friday, May 16th. One equities research analyst has rated the stock with a sell rating, thirteen have given a hold rating and eleven have issued a buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Hold" and a consensus target price of $80.20.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.